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BACKGROUND: The risk of recurrent stroke is up to 10% in
the week after a transient ischaemic attack (TIA) or minor
stroke. Modelling studies suggest that urgent use of existing
preventive treatments could reduce the risk by 80-90%, but
in the absence of evidence many health-care systems make
little provision. Our aim was to determine the effect of more
rapid treatment after TIA and minor stroke in patients who
are not admitted direct to hospital. M E T H O D S : We did a
prospective before (phase 1: April 1, 2002, to Sept 30,
2004) versus after (phase 2: Oct 1, 2004, to March 31,
2007) study of the effect on process of care and outcome of
more urgent assessment and immediate treatment in clinic,
rather than subsequent initiation in primary care, in all
patients with TIA or minor stroke not admitted direct to
hospital. The study was nested within a rigorous population-
based incidence study of all TIA and stroke (Oxford Vascular
Study;  OXVASC), such that case ascerta inment,
investigation, and follow-up were complete and identical in
both periods. The primary outcome was the risk of stroke
within 90 days of first seeking medical attention, with
EFFECT OF URGENT TREATMENT OF TRANSIENT ISCHAEMIC ATTACK AND MINOR STROKE
ON EARLY RECURRENT STROKE (EXPRESS STUDY): A PROSPECTIVE POPULATION-BASED
SEQUENTIAL COMPARISON.
COMMENTARY
Approximately 15% of ischemic strokes are preceded by a transient ischemic attack (TIA). The early estimated risk of stroke
after a TIA is 8-12% at seven days and 11-15% at one month. A study from California done on the short-term prognosis of
transient ischemic attacks revealed that in a 90-day period after a TIA, one in nine patients had a stroke and half of all the
strokes occurred in the first 2 days. TIAs should be considered a neurologic emergency and a harbinger of stroke. 
The EXPRESS and FASTER studies have yielded some interesting insights in the treatment of transient ischemic attacks.
The EXPRESS study is a sequential population-based interventional study nested in the population of the OXVASC study
such that the case ascertainment, investigation and follow-up were complete and identical in both cases. There were 1278
patients that were studied, those in the first phase had a delay in seeking medical care and those in the second phase
were referred to a study clinic and received immediate attention and preventive care. The 90-day risk of recurrent stroke
dropped from 10.3% to 2.1%. This reduction was independent of age and sex, and early treatment did not increase the
risk of intracerebral hemorrhage. Although the second study FASTER - a 4x4 factorial design testing the intervention of
clopidrogel loading plus simvastatin after TIA - failed to reach statistical significance of efficacy due to poor enrollment, it
did demonstrate the safety of early treatment.
These two studies together demonstrate a relative risk reduction of 80-90% in the emergent risk of stroke by the prompt
treatment of TIA. They merit our attention and a paradigm shift in our strategy for treating transient ischemic attacks is
called for.
Ayeesha K. Kamal
Assistant Professor of Neurology
Aga Khan University
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independent blinded (to study period) audit of all events.
FINDINGS: Of the 1278 patients in OXVASC who presented
with TIA or stroke (634 in phase 1 and 644 in phase 2), 607
were referred or presented direct to hospital, 620 were
referred for outpatient assessment, and 51 were not referred
to secondary care. 95% (n=591) of all outpatient referrals
were to the study clinic. Baseline characteristics and delays
in seeking medical attention were similar in both periods, but
median delay to assessment in the study clinic fell from 3
(IQR 2-5) days in phase 1 to less than 1 (0-3) day in phase
2 (p<0.0001), and median delay to first prescription of
treatment fe ll  from 20 (8-53) days to 1 (0-3) day
(p<0.0001). The 90-day risk of recurrent stroke in the
patients referred to the study clinic was 10.3% (32/310
patients) in phase 1 and 2.1% (6/281 patients) in phase 2
(adjusted hazard ratio 0.20, 95% CI 0.08-0.49; p=0.0001);
there was no significant change in risk in patients treated
elsewhere. The reduction in risk was independent of age and
sex, and early treatment did not increase the risk of
int racerebra l haemorrhage or other  b leeding.
INTERPRETATION: Early initiation of existing treatments after
TIA or minor stroke was associated with an 80% reduction in
the risk of early recurrent stroke. Further follow-up is required
to determine long-term outcome, but these results have
immediate implications for service provision and public
education about TIA and minor stroke.
B A C K G R O U N D : Patients with transient ischaemic attack
(TIA) or minor stroke are at high immediate risk of stroke.
The optimum early treatment options for these patients are
not known. METHODS: Within 24 h of symptom onset, we
randomly assigned, in a factorial design, 392 patients with
TIA or minor stroke to clopidogrel (300 mg loading dose then
75 mg daily; 198 patients) or placebo (194 patients), and
simvastatin (40 mg daily; 199 patients) or placebo (193
patients). All patients were also given aspirin and were
followed for 90 days. Descriptive analyses were done by
intention to treat. The primary outcome was total stroke
(ischaemic and haemorrhagic) within 90 days. Safety
outcomes included haemorrhage related to clopidogrel and
myositis related to simvastatin. This study is registered as an
International Standard Randomised Controlled Trial (number
35624812) and with ClinicalTrials.gov (NCT00109382).
FINDINGS: The median time to stroke outcome was 1 day
(range 0-62 days). The trial was stopped early due to a
failure to recruit patients at the prespecified minimum
enrolment rate because of increased use of statins. 14
(7.1%) patients on clopidogrel had a stroke within 90 days
compared with 21 (10.8%) patients on placebo (risk ratio
0.7 [95% CI 0.3-1.2]; absolute risk reduction -3.8% [95% CI
-9.4 to 1.9]; p=0.19). 21 (10.6%) patients on simvastatin
had a stroke within 90 days compared with 14 (7.3%)
patients on placebo (risk ratio 1.3 [0.7-2.4]; absolute risk
increase 3.3% [-2.3 to 8.9]; p=0.25). The interaction
between clopidogrel and simvastatin was not significant
(p=0.64). Two patients on clopidogrel had intracranial
haemorrhage compared with none on placebo (absolute risk
increase 1.0% [-0.4 to 2.4]; p=0.5). There was no
difference between groups for the simvastatin safety
outcomes. INTERPRETATION: Immediately after TIA or minor
stroke, patients are at high risk of stroke, which might be
reduced by using clopidogrel in addition to aspirin. The
haemorrhagic risks of the combination of aspirin and
clopidogrel do not seem to offset this potential benefit. We
were unable to provide evidence of benefit of simvastatin in
this setting. This aggressive prevention approach merits
further study.
Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators.
Acute Stroke Programme, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Lancet Neurol. 2007 Nov;6(11):961-9.
FAST ASSESSMENT OF STROKE AND TRANSIENT ISCHAEMIC ATTACK TO PREVENT EARLY
RECURRENCE (FASTER): A RANDOMISED CONTROLLED PILOT TRIAL.
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NEURORADIOLOGY
COMMENTARY
The first of this issue's selections tries to answer a seemingly unanswerable question. What to do with unruptured,
incidentally-diagnosed intracranial aneurysms? There is general consensus that lesions greater than 10 mm should be
treated but what of the smaller aneurysms? Gallas et al report their experience of endovascularly treating 321 unruptured
aneurysms, the majority (76%) of which were under 10 mm in diameter. Although they conclude that endovascular
treatment is “an attractive option for treatment of unruptured aneurysms,” this is not supported by their reported morbidity
of 14.4% with five deaths due to aneurysm perforation during the procedure. Of the 302 aneurysms for which follow-up
was available, 85 were deemed either to be subtotally (n=80) or incompletely (n=5) treated. Even after this article the
question of what to do with small incidental aneurysms remains unanswered.
Bendel et al writing in Radiology, on the other hand, provide yet more data that points to endovascular treatment having
benefits over surgical options in aneurysmal subarachnoid hemorrhage. In a randomized cohort, the patients undergoing
endovascular treatment had fewer MR abnormalities at one year, as compared to those having surgery. These changes
correlated with performance on neuropsychological tests.
Laslo et al have pointed to the potential use of perfusion imaging in prognostication following subarachnoid hemorrhage.
Using transit time analysis they were able to predict development of vasospasm in an animal model. If these data can be
replicated in humans then this will be a novel way to assess vasospasm. And as opposed to transcranial doppler, there is
low inter-observer variability with a high degree of reproducibility.
The final abstract also refers to the high degree of inter-observer reproducibility in most multi-detector CT studies. This time
the target is carotid disease. Using standardized reporting, the authors were able to achieve a high degree of inter-observer
agreement. 
Zafar Sajjad
Associate Professor of Neuroradiology
Aga Khan University
S. Gallasa, J. Drouineaub, J. Gabrillarguesc, A. Pascod, C. Cognarde, L. Pierota and D. Herbreteauf
a Department of Neuroradiology Hospitalier Universitaire Maison Blanche, Reims, France
b Department of Radiology A, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
c Department of Radiology, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France
d Department of Radiology, Centre Hospitalier Universitaire d'Angers, Angers, France
e Department of Neuroradiology, Centre Hospitalier de Toulouse, Hôpital Purpan, Toulouse, France
f Department of Neuroradiology, Centre Hospitalier de Tours, Tours, France 
American Journal of Neuroradiology 29:63-68, January 2008
FEASIBILITY, PROCEDURAL MORBIDITY AND MORTALITY, AND LONG-TERM FOLLOW-UP OF
ENDOVASCULAR TREATMENT OF 321 UNRUPTURED ANEURYSMS
BACKGROUND AND PURPOSE: The purpose of our study
was to evaluate the technical feasibility, morbidity and
mortal ity, and durab il it y o f  occlus ion of  unruptured
aneurysms treated with Guglielmi detachable coils (GDCs)
with a long-term follow-up. MATERIALS AND METHODS:
Between January 1998 and January 2005, we treated 321
unruptured aneurysms with GDCs in 5 neuroradiologic
insti tutions. During this period, 63% of unruptured
aneurysms were treated by endovascular  technique.
Procedural feasibility, technical complications, morbidity and
mortality, and acute and long-term angiographic occlusion
were assessed. R E S U L T S : Overall technical feasibility of
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Paula Bendel, MD, Timo Koivisto, MD, PhD, Mervi Könönen, MSc, Tuomo Hänninen, MSc, PhD, Heleena
Hurskainen, MSc, Tapani Saari, MD, Matti Vapalahti, MD, PhD, Juha Hernesniemi, MD, PhD, and Ritva Vanninen,
MD, PhD 
Departments of Clinical Radiology (P.B., M.K., T.S., R.V.), Neurosurgery (T.K., H.H., M.V., J.H.), and Neurology (T.H.), Kuopio University Hospital and Kuopio
University, Puijonlaaksontie 2, 70210 Kuopio, Finland; and Department of Neurosurgery, University of Helsinki, Helsinki, Finland (J.H.). 
Radiology 2008;246:543-552
MR IMAGING OF THE BRAIN 1 YEAR AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE:
RANDOMIZED STUDY COMPARING SURGICAL WITH ENDOVASCULAR TREATMENT
coiling treatment was 94%; 302 aneurysms were treated by
endovascular technique. At the end of the initial procedure,
acute occlusion was classified as complete in 207 cases
(70%), subtotal in 84 cases (26.1%), and incomplete in 11
cases (3.9%). Ischemic complications were observed in 28
patients (9%); 8 patients (2.6%) had perforation of their
aneurysms. Treatment-related morbidity was 14.4%, and
morbidity with clinical complications was evaluated at 7.7%
(n = 23 patients). Five patients (1.7%) died as a result of
aneurysm perforation. Final follow-up angiograms, after 9
secondary treatments, demonstrated complete occlusion in
193 patients (69.5%), subtotal in 80 aneurysms (28.5%),
and incomplete occlusion in 5 (1.8%). Nineteen patients
were lost to follow-up (6.3%). C O N C L U S I O N : E n d o v a s c u l a r
coiling with detachable coils is an attractive option for
treatment of unruptured aneurysms. This method of
treatment is safe with a low rate of complications.
Prospective studies with longer follow-up periods are needed
to assess the long-term durability of occlusion in unruptured
aneurysms.
Purpose:  To prospectively  evaluate, wi th magnet ic
resonance (MR) imaging, long-term outcome of the brain
after endovascular versus neurosurgical treatment for
aneurysmal subarachnoid hemorrhage (aSAH). M a t e r i a l s
and Methods: Institutional review board approval and
informed consent were obtained. One hundred sixty-eight
(77 men, 91 women; mean age ± standard deviation, 51
years ± 13) patients were randomly assigned to surgical
versus endovascular treatment of the ruptured aneurysm with
138 (67 endovascular, 71 surgical) MR examinations 1 year
after aSAH. The presence, localization, volumes, and cause
of lesions were analyzed with  2, Mann-Whitney U, and
Student t tests. Furthermore, correlation between MR-
detectable brain parenchymal high-signal intensity (SI)
lesions on T2- and intermediate-weighted MR images and
neuropsychologic outcome was evaluated by using Spearman
correlation coefficient. Results: Only 44 (31.9%) of 138
patients had no lesions associated with aSAH. According to
intention to treat, lesions were more frequent after surgical
rather than endovascular treatment, predominating in the
frontal (surgical: n = 50, [70.4%] vs endovascular: n = 34
[50.7%], P = .018) and temporal (n = 34 [47.9%] vs n =
15 [22.4%], P = .002) lobes. Only endovascular patients
had subtentorial lesions (n = 4 [6.0%], P = .037). Ischemic
lesions in the parental artery territory were more frequent in
surgical (n = 33 [46.5%]) than in endovascular (n = 15
[22.4%], P = .003) patients, with corresponding mean
lesion volumes of 20.9 cm3 ± 46.5 versus 17.6 cm3 ±
35.8 (P = .209). Ischemic lesions in remote vascular
territories were equal in frequency and size. Retraction
injuries were common in the surgical (n = 40, [56.3%])
treatment group. Ischemic lesion volumes correlated with
neuropsychologic test scores. C o n c l u s i o n : P a r e n c h y m a l
high-SI lesions on T2- and intermediate-weighted MR images
are more f requent  after ear ly surgical  rather than
endovascular treatment of the ruptured aneurysm, and lesion
volumes correlate with the neuropsycholog ic  test
performance.
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BACKGROUND AND PURPOSE: There are limited indicators
available to predict cerebral vasospasm in patients with
subarachnoid hemorrhage (SAH). The purpose of this study
was to determine if CT perfusion-derived hemodynamic
parameters are predictors of vasospasm severity and
outcome after experimenta l SAH. MATERIALS AND
M E T H O D S : SAH was induced in 25 New Zealand white
rabbits. Cerebral blood flow (CBF), cerebral blood volume
(CBV), and mean transit time (MTT) were measured with CT
perfusion before SAH, within 1 hour after SAH, and on days
2, 4, 7, 9, and 16 after SAH. Basilar artery diameter,
measured with CT angiography and neurologic scoring, was
also obtained on the same days. Differences between
animals with moderate-severe delayed vasospasm ( 24%
basilar artery narrowing) and mild delayed vasospasm
(<24% basilar artery narrowing) were investigated with
repeated measures analysis of variance. Multiple linear
regression analysis was used to investigate the relationship
between CT perfusion parameters (CBF, CBV, MTT), basilar
artery diameter, and neurologic score. R E S U L T S : M T T
increase <1 hour after SAH independently predicted
mortality within 48 hours of SAH (P < .05). MTT and
neurologic deficits were significantly greater with moderate-
severe than with mild vasospasm (P < .05). MTT on day 2,
but not CBF or  CBV, was a signi f icant  pred ictor o f
subsequent moderate-severe delayed vasospasm (P < .05). 
CONCLUSION: In the rabbit model of experimental SAH, the
CT-derived hemodynamic parameter MTT on day 0 predicted
early mortality, and MTT on day 2 predicted development of
moderate-severe de layed vasospasm. MTT was also
significantly correlated with arterial diameter and neurologic
score.
A.M. Lasloa,b,c, J.D. Eastwoodd, P. Pakkiric, F. Chena,b,c and T.Y. Leea,b,c
a Imaging Division, Lawson Health Research Institute, London, Ontario, Canada
b Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
c Imaging Research Laboratories, Robarts Research Institute, London, Ontario, Canada
d Department of Radiology, Duke University Medical Center, Durham, NC 
American Journal of Neuroradiology 29:79-85,
CT PERFUSION-DERIVED MEAN TRANSIT TIME PREDICTS EARLY MORTALITY AND DELAYED
VASOSPASM AFTER EXPERIMENTAL SUBARACHNOID HEMORRHAGE
OBJECTIVE. Atherosclerotic disease of the carotid arteries is
one of the most important causes of stroke. Our objective
was to evaluate the interobserver agreement in the
measurement of the degree of carotid plaque stenosis by
using MDCT angiography (MDCTA) and the effects produced
using different window parameters and by the different types
of plaque. MATERIALS AND METHODS. From June 2005 to
June 2006, we retrospectively evaluated 215 patients (151
men, 64 women) who underwent MDCTA for the study of
carotid arteries. In all patients we measured degree of
stenosis, applying the criteria of the North American
Symptomatic Carotid Endarterectomy Trial (NASCET). Each
patient was studied independently by two observers. We
used three window settings for the measurements. We
grouped the measurements according to the type of plaque.
Obtained data were then analyzed to calculate the
interobserver agreement and the kappa value. R E S U L T S .
Kappa values for the degree of stenosis evaluation were
0.696, 0.79, and 0.775 for window settings 1, 2, and 3,
respectively. The best agreement was observed in the
assessment of fatty plaque, whereas the presence of
calcification produced disagreement. C O N C L U S I O N . W e
observed a very good interobserver agreement in the
evaluation of degree of stenosis using MDCTA with the
application of specific visualization parameters. Our data
suggested that MDCTA can provide reproducible values. 
Luca Saba1 and Giorgio Mallarini1,2
1 Department of Science of the Images, Policlinico Universitario, s.s. 554 Monserrato, Cagliari 09045, Italy.
2 Institute of Radiology of the University of Cagliari, 46 Hospital St., Cagliari 09126, Italy.
AJR 2008; 190:W41-W46
MDCTA OF CAROTID PLAQUE DEGREE OF STENOSIS: EVALUATION OF INTEROBSERVER
AGREEMENT
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Background Depression may increase the risk of mortality
among certain subgroups of older people, but the part played
by antidepressants in this association has not been
thoroughly explored. Aims To identify the characteristics of
older populations who are most at risk of dying, as a function
of depressive symptoms, gender and antidepressant use.
Method Adjusted Cox proportional hazards models were used
to determine the association between depression and/or
antidepressant use and 4-year survival of 7363 community-
dwelling elderly people. Major depressive disorder was
evaluated using a standardised psychiatric examination
based on DSM-IV criteria and depressive symptoms were
assessed using the Center for Epidemiological Studies-
Depression scale.  Results Depressed men using
antidepressants had the greatest risk  of dying, with
increasing depression severity corresponding to a higher
hazard risk. Among women, only severe depression in the
absence of treatment was significantly associated with
mortality. Conclusions The association between depression
and mortality is gender-dependent and varies according to
symptom load and antidepressant use.
Ryan J, Carriere I, Ritchie K, Stewart R, Toulemonde G, Dartigues JF, Tzourio C, Ancelin ML
INSERM U888, Nervous System Pathologies, Hôpital La Colombière, P42, 34093 Montpellier Cedex 5, France. 
Br J Psychiatry. 2008 Jan;192:12-8.




It is well known for some time that depression in the elderly increases the risk of mortality. Ryan et al have further explored
this issue in terms of gender and antidepressant use. They showed that depressed males using antidepressants are at the
highest risk of dying - the greater the severity of depression the higher the risk. In women severe depression was
significantly associated with dying in the absence of treatment. This highlights the importance of treating depression in this
age group.
Placebo and nocebo effects, the therapeutic and adverse effects, respectively, of inert substances, are of great interests to
psychiatrists as several psychiatric illnesses have a placebo response rate as high as 40 % in randomized clinical trials. It
has long been suspected that placebo response is not just a psychological phenomenon but has a neural basis. Scott and
colleagues demonstrate that high placebo responses were associated with greater dopaminergic and opioid activity in the
basal ganglia while nocebo responses were associated with a deactivation of dopamine and opioid release.
While the discovery of anti-dementia drugs has brought some temporary relief to some of the patients with dementia, by
and large dementia remains a relentlessly progressive disease with death as the final outcome. Xie and colleagues show
that after the onset of dementia the median survival time is 4.5 years. The survival time is slightly longer for women and is
positively correlated with the age of onset of dementia, the earlier the onset the longer the survival time. 
Syed Ahmer
Assistant Professor of Psychiatry
Aga Khan University
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C O N T E X T : Placebo and nocebo effects, the therapeutic and
adverse effects, respectively, of inert substances or sham
procedures, represent serious confounds in the evaluation of
therapeutic interventions. They are also an example of
cognitive processes, particularly expectations, capable of
influencing phys iology. O B J E C T I V E : To examine the
contribution of 2 different neurotransmitters, the endogenous
opioid and the dopaminergic (DA) systems, to the
development of placebo and nocebo effects. DESIGN AND
S E T T I N G : Using a within-subject design, subjects twice
underwent a 20-minute standardized pain challenge, in the
absence and presence of a placebo with expected analgesic
properties. Studies were conducted in a university hospital
setting. PARTICIPANTS: Twenty healthy men and women aged
20 to 30 years recruited by advertisement. MAIN OUTCOME
M E A S U R E S : Activation of DA and opioid neurotransmission by
a pain stressor with and without placebo (changes in the
binding potential of carbon 11 [11C]-labeled raclopride and
[11C] carfentanil with positron emission tomography) and
ratings of pain, affective state, and anticipation and perception
of analgesia. RESULTS: Placebo-induced activation of opioid
neurotransmission was detected in the anterior cingulate,
orbitofrontal and insular cortices, nucleus accumbens,
amygdala, and periaqueductal gray matter. Dopaminergic
activation was observed in the ventral basal ganglia, including
the nucleus accumbens. Regional DA and opioid activity were
associated with the anticipated and subjectively perceived
effectiveness of the placebo and reductions in continuous pain
ratings. High placebo responses were associated with greater
DA and opioid activity in the nucleus accumbens. Nocebo
responses were associated with a deactivation of DA and
opioid release. Nucleus accumbens DA release accounted for
25% of the variance in placebo analgesic effects.
CONCLUSIONS: Placebo and nocebo effects are associated
with opposite responses of DA and endogenous opioid
neurotransmission in a distributed network of regions. The
brain areas involved in these phenomena form part of the
circuit typically implicated in reward responses and motivated
b e h a v i o r .
Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK
Department of Psychiatry and Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor 48109-0720, USA
Arch Gen Psychiatry. 2008 Feb;65(2):220-31
PLACEBO AND NOCEBO EFFECTS ARE DEFINED BY OPPOSITE OPIOID AND DOPAMINERGIC
RESPONSES
O B J E C T I V E S : To provide estimates of survival after onset of
dementia by age, sex, self reported health, disability, and
severity of cognitive impairment. DESIGN: Analysis of
participants from prospective population based cohort study in
1991-2003, with follow-up of dementia status in all individuals
after two and six years (in one centre) and 10 years and in
subsamples additionally at six and eight years and mortality
until 2005. S E T T I N G : Multicentre population based study in
England and Wales: two rural and three urban centres.
PARTICIPANTS: 438 participants who developed dementia
from a population based study of 13 004 individuals aged 65
years and over drawn from primary care population registers.
MAIN OUTCOME MEASURES: Sociodemographic factors,
cognitive function, specific health conditions, and self reported
health collected at each interview. Cox's proportional hazards
regression models were used to identify predictors of mortality
from the selected variables in people who received diagnosis of
dementia according the study's criteria. R E S U L T S : B y
December 2005, 356 of the 438 (81%) participants who
developed dementia during the study had died. Estimated
median survival time from onset of dementia to death was 4.1
years (interquartile range 2.5-7.6) for men and 4.6 years (2.9-
7.0) for women. There was a difference of nearly seven years
in survival between the younger old and the oldest people with
dementia: 10.7 (25th centile 5.6) for ages 65-69; 5.4
(interquartile range 3.4-8.3) for ages 70-79; 4.3 (2.8-7.0) for
ages 80-89, and 3.8 (2.3-5.2) years for ages > or =90.
Significant factors that predicted mortality in the presence of
dementia during the follow-up included sex, age of onset, and
disability. C O N C L U S I O N : These analyses give a population
based estimated median survival for incident dementia of 4.5
years. Such estimates can be used for prognosis and planning
for patients, carers, service providers, and policy makers.
Xie J, Brayne C, Matthews FE; Medical Research Council Cognitive Function and Ageing Study collaborators.
Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Cambridge CB2 0SR.
BMJ. 2008 Feb 2;336(7638):258-62.
SURVIVAL TIMES IN PEOPLE WITH DEMENTIA: ANALYSIS FROM POPULATION BASED
COHORT STUDY WITH 14 YEAR FOLLOW-UP.
